CY1105758T1 - Τροποποιημενη απιμιναση αργινινης - Google Patents
Τροποποιημενη απιμιναση αργινινηςInfo
- Publication number
- CY1105758T1 CY1105758T1 CY20061101590T CY061101590T CY1105758T1 CY 1105758 T1 CY1105758 T1 CY 1105758T1 CY 20061101590 T CY20061101590 T CY 20061101590T CY 061101590 T CY061101590 T CY 061101590T CY 1105758 T1 CY1105758 T1 CY 1105758T1
- Authority
- CY
- Cyprus
- Prior art keywords
- modified arginine
- deamination
- arginine deamination
- methods
- treating
- Prior art date
Links
- 150000001483 arginine derivatives Chemical class 0.000 title 1
- 230000009615 deamination Effects 0.000 title 1
- 238000006481 deamination reaction Methods 0.000 title 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03006—Arginine deiminase (3.5.3.6)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4620097P | 1997-05-12 | 1997-05-12 | |
| US09/023,809 US6183738B1 (en) | 1997-05-12 | 1998-02-13 | Modified arginine deiminase |
| PCT/US1998/009575 WO1998051784A1 (en) | 1997-05-12 | 1998-05-12 | Modiified arginine deiminase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105758T1 true CY1105758T1 (el) | 2010-12-22 |
Family
ID=26697638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101590T CY1105758T1 (el) | 1997-05-12 | 2006-11-03 | Τροποποιημενη απιμιναση αργινινης |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US6183738B1 (https=) |
| EP (1) | EP0981607B1 (https=) |
| JP (1) | JP4456184B2 (https=) |
| CN (1) | CN1169951C (https=) |
| AT (1) | ATE335814T1 (https=) |
| AU (1) | AU724907B2 (https=) |
| CA (1) | CA2288948C (https=) |
| CY (1) | CY1105758T1 (https=) |
| DE (1) | DE69835515T2 (https=) |
| DK (1) | DK0981607T3 (https=) |
| ES (1) | ES2270515T3 (https=) |
| PT (1) | PT981607E (https=) |
| TW (1) | TW368504B (https=) |
| WO (1) | WO1998051784A1 (https=) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545553A (en) * | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US6635462B1 (en) * | 1997-05-12 | 2003-10-21 | Phoenix Pharmacologies, Inc. | Mutated form of arginine deiminase |
| US5985263A (en) * | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| CN1328152A (zh) * | 2000-06-14 | 2001-12-26 | 上海博德基因开发有限公司 | 一种新的多肽——人nrd转化酶10.01和编码这种多肽的多核苷酸 |
| US20040096437A1 (en) * | 2000-07-27 | 2004-05-20 | Bon-Hong Min | Pharmaceutical composition comprising arginine deiminasa for inhibiting angio-genesis |
| WO2002009741A1 (en) * | 2000-07-27 | 2002-02-07 | Angiolab, Inc. | The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis |
| KR20040004449A (ko) * | 2000-11-28 | 2004-01-13 | 휘닉스 파머컬러직스, 인크. | 변형된 아르기닌 데이미나제 |
| US20050063942A1 (en) * | 2001-02-02 | 2005-03-24 | Clark Mike A. | Methods for predicting sensitivity of tumors to arginine deprivation |
| US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7399613B2 (en) * | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
| US7173003B2 (en) * | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| ES2411007T3 (es) * | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| US7795210B2 (en) * | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| US7265084B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| US7696163B2 (en) * | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7179617B2 (en) * | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
| US7473680B2 (en) | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
| DE60336555D1 (de) * | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
| CN100405906C (zh) * | 2002-10-09 | 2008-07-30 | 尼奥斯技术有限公司 | 促红细胞生成素:促红细胞生成素的重构和糖缀合 |
| WO2004046309A2 (en) * | 2002-11-18 | 2004-06-03 | Phoenix Pharmacologics, Inc. | Methods for inhibiting viral replication in vivo |
| US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| JP4490369B2 (ja) | 2002-12-31 | 2010-06-23 | ネクター セラピューティクス アラバマ，コーポレイション | マレアミド酸ポリマー誘導体及びこれらの生物学的複合体 |
| MXPA05007151A (es) * | 2002-12-31 | 2005-09-21 | Nektar Therapeutics Al Corp | Polimeros terminados en maleimida hidroliticamente estables. |
| NZ542094A (en) * | 2003-03-14 | 2008-12-24 | Neose Technologies Inc | Branched polymer conjugates comprising a peptide and water-soluble polymer chains |
| EP1613261A4 (en) * | 2003-04-09 | 2011-01-26 | Novo Nordisk As | INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| PL1615945T3 (pl) * | 2003-04-09 | 2012-03-30 | Ratiopharm Gmbh | Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami |
| CN100522988C (zh) * | 2003-04-09 | 2009-08-05 | 诺和诺德公司 | 糖peg化方法及由该方法生产的蛋白质/肽 |
| JP2007523630A (ja) | 2003-05-09 | 2007-08-23 | ネオス テクノロジーズ インコーポレイテッド | ヒト成長ホルモングリコシル化突然変異体の組成と調合法 |
| US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
| US8633157B2 (en) * | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| EP1694347B1 (en) * | 2003-11-24 | 2013-11-20 | BioGeneriX AG | Glycopegylated erythropoietin |
| US7842661B2 (en) * | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| RU2400490C2 (ru) * | 2003-12-03 | 2010-09-27 | Биодженерикс Аг | Гликопэгилированный гранулоцитарный колониестимулирующий фактор |
| CN1897812B (zh) * | 2003-12-03 | 2011-08-17 | 生物种属学股份公司 | 糖聚乙二醇化的粒细胞集落刺激因子 |
| US20080318850A1 (en) * | 2003-12-03 | 2008-12-25 | Neose Technologies, Inc. | Glycopegylated Factor Ix |
| US7790835B2 (en) | 2003-12-03 | 2010-09-07 | Nektar Therapeutics | Method of preparing maleimide functionalized polymers |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| US7956032B2 (en) * | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| NZ548123A (en) * | 2004-01-08 | 2010-05-28 | Novo Nordisk As | O-linked glycosylation of peptides |
| WO2005107815A2 (en) * | 2004-05-03 | 2005-11-17 | Nektar Therapeutics Al, Corporation | Polymer derivatives comprising an imide branching point |
| KR20070008645A (ko) * | 2004-05-04 | 2007-01-17 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 폴리펩티드의 ｏ-연결된 단백당형 및 그들의 제조 방법 |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| CN1745847A (zh) * | 2004-09-08 | 2006-03-15 | 康达医药科技有限公司 | 用精氨酸酶治疗肝炎的药物组合物和方法 |
| WO2006031811A2 (en) * | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| EP1797192A1 (en) * | 2004-09-29 | 2007-06-20 | Novo Nordisk Health Care AG | Modified proteins |
| WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| JP2008526864A (ja) * | 2005-01-06 | 2008-07-24 | ネオス テクノロジーズ インコーポレイテッド | 糖断片を用いる糖結合 |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| JP2008538181A (ja) * | 2005-03-30 | 2008-10-16 | ネオス テクノロジーズ インコーポレイテッド | 昆虫細胞系において増殖させたペプチドを生産するための製造方法 |
| WO2006121569A2 (en) * | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| FR2884717B1 (fr) * | 2005-04-25 | 2009-07-03 | Erytech Pharma Soc Par Actions | Erythrocytes renfermant de l'arginine deiminase |
| EP2975135A1 (en) | 2005-05-25 | 2016-01-20 | Novo Nordisk A/S | Glycopegylated factor IX |
| DE602006013151D1 (de) * | 2005-07-19 | 2010-05-06 | Nektar Therapeutics | Verfahren zur herstellung von polymermaleimiden |
| US20070105755A1 (en) * | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| MX2008002395A (es) * | 2005-08-19 | 2008-03-18 | Neose Technologies Inc | Factor vii y factor viia glicopegilados. |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| CN101002945B (zh) * | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
| AU2007245190B2 (en) | 2006-03-31 | 2011-07-21 | Takeda Pharmaceutical Company Limited | Pegylated factor VIII |
| US7982010B2 (en) * | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
| US7645860B2 (en) * | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| US7985839B2 (en) * | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| EP2049144B8 (en) * | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylation of peptides via o-linked glycosylation sequences |
| EP2054521A4 (en) * | 2006-10-03 | 2012-12-19 | Novo Nordisk As | PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES |
| ES2655734T3 (es) * | 2006-10-04 | 2018-02-21 | Novo Nordisk A/S | Glicopéptidos y azúcares pegilados unidos a glicerol |
| US20080207487A1 (en) * | 2006-11-02 | 2008-08-28 | Neose Technologies, Inc. | Manufacturing process for the production of polypeptides expressed in insect cell-lines |
| PT2101821E (pt) | 2006-12-15 | 2014-10-03 | Baxter Int | Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo |
| HRP20130382T1 (hr) * | 2007-04-03 | 2013-05-31 | Biogenerix Ag | Postupci lijeäśenja pomoä†u glikopegiliranog g-csf |
| US20090053167A1 (en) * | 2007-05-14 | 2009-02-26 | Neose Technologies, Inc. | C-, S- and N-glycosylation of peptides |
| US20080292609A1 (en) * | 2007-05-21 | 2008-11-27 | Ning Man Cheng | Use of Arginase in Combination with 5FU and Other Compounds for Treatment of Human Malignancies |
| WO2008151258A2 (en) * | 2007-06-04 | 2008-12-11 | Neose Technologies, Inc. | O-linked glycosylation using n-acetylglucosaminyl transferases |
| CA2690611C (en) * | 2007-06-12 | 2015-12-08 | Novo Nordisk A/S | Improved process for the production of nucleotide sugars |
| FR2919804B1 (fr) | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
| US7560263B2 (en) | 2007-08-17 | 2009-07-14 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| US8207112B2 (en) * | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| CA2711503A1 (en) * | 2008-01-08 | 2009-07-16 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
| PL2257311T3 (pl) | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Koniugaty cząsteczek czynnika VIII |
| WO2010014225A2 (en) * | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| US8815232B2 (en) | 2008-08-26 | 2014-08-26 | Kyon Biotech Ag | Compositions and methods for treating cancer |
| US20100150949A1 (en) * | 2008-12-16 | 2010-06-17 | Oncopharmacologics, Inc. | Methods and compositions for modulating proline levels |
| JP5909755B2 (ja) | 2009-07-27 | 2016-04-27 | リポクセン テクノロジーズ リミテッド | 非血液凝固タンパク質の糖ポリシアル酸化 |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| EP3093029A1 (en) | 2009-07-27 | 2016-11-16 | Baxalta GmbH | Blood coagulation protein conjugates |
| ES2597954T3 (es) * | 2009-07-27 | 2017-01-24 | Baxalta GmbH | Conjugados de proteína de la coagulación sanguínea |
| EP2295560A1 (en) | 2009-09-14 | 2011-03-16 | RWTH Aachen University | Directed evolution of arginine deiminase for increased activity at physiological pH |
| ES2690542T3 (es) | 2010-02-04 | 2018-11-21 | Biomarin Pharmaceutical Inc. | Método para purificar variantes de fenilalanina amoníaco-liasa procariotas |
| CN101812438B (zh) * | 2010-03-25 | 2014-08-27 | 江苏泰康生物医药有限公司 | 一种精氨酸脱亚氨酶突变体及其制备与应用 |
| US20120148559A1 (en) | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
| BR112013015898A2 (pt) | 2010-12-22 | 2018-06-26 | Baxter International Inc. | derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada. |
| EP2834262B1 (en) * | 2012-04-04 | 2020-09-02 | Polaris Group | Composition comprising pegylated arginine deiminase |
| WO2014001956A2 (en) * | 2012-06-25 | 2014-01-03 | Ning Man Cheng | Combinational use of pegylated recombinant human arginase with chemotherapeutic/target therapeutic drug in cancer treatment |
| US9255262B2 (en) | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
| USRE48805E1 (en) | 2013-03-06 | 2021-11-02 | Vision Global Holdings Ltd. | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein |
| WO2014151982A2 (en) * | 2013-03-15 | 2014-09-25 | Polaris Group | Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment |
| WO2015051340A1 (en) | 2013-10-04 | 2015-04-09 | Ann David K | Methods for treating breast and other cancers by targeting argininosuccinate synthetase 1-deficiency |
| TWI676683B (zh) * | 2014-03-14 | 2019-11-11 | 開曼群島商瑞華藥業集團 | 用於癌症治療之對ａｄｉ－ｐｅｇ２０抗體交叉反應性降低之精胺酸去亞胺酶 |
| WO2015143006A1 (en) * | 2014-03-18 | 2015-09-24 | Tdw Group | Engineered chimeric pegylated adi and methods of use |
| CN103923898A (zh) * | 2014-04-17 | 2014-07-16 | 江南大学 | 一种peg修饰的重组精氨酸脱亚胺酶及其制备方法和应用 |
| CN107108723B (zh) | 2014-07-08 | 2021-11-12 | 瑞华药业集团 | 精氨基琥珀酸合成酶的抗体和相关方法 |
| EP4104853B1 (en) | 2014-09-16 | 2026-05-06 | Polaris Group | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment |
| CN104726478A (zh) * | 2015-03-09 | 2015-06-24 | 武汉远大弘元股份有限公司 | 表达精氨酸脱亚胺酶基因的重组大肠杆菌及其应用 |
| EP3344575B1 (en) | 2015-09-04 | 2020-04-15 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| CA3023092A1 (en) | 2016-05-03 | 2017-11-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to induce tolerance |
| CN119950689A (zh) | 2016-07-05 | 2025-05-09 | 北极星药业集团股份有限公司 | 使用精氨酸耗竭剂的组合癌症免疫疗法 |
| TWI784982B (zh) | 2016-11-02 | 2022-12-01 | 開曼群島商北極星藥業集團股份有限公司 | 聚乙二醇化精胺酸脫亞胺酶之調配物 |
| CN106591271B (zh) * | 2017-03-02 | 2019-07-16 | 江南大学 | 一株酶活和温度稳定性提高的精氨酸脱亚胺酶突变体及其应用 |
| WO2019042628A1 (en) | 2017-08-31 | 2019-03-07 | Erytech Pharma | ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY |
| EP3449935A1 (en) | 2017-08-31 | 2019-03-06 | Erytech Pharma | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
| AU2019275733B2 (en) * | 2018-05-31 | 2025-07-31 | The Chinese University Of Hong Kong | Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities |
| CN118497178A (zh) * | 2023-02-15 | 2024-08-16 | 重庆派金生物科技有限公司 | 精氨酸脱亚胺酶突变体、共价二聚体及其偶联物和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US5447722A (en) | 1983-12-12 | 1995-09-05 | University Of Manitoba | Method for the suppression of an immune response with antigen-MPEG conjugates in nonsensitized individuals |
| EP0230777B1 (en) * | 1985-12-28 | 1991-04-10 | Ohgen Research Laboratories Ltd., | Antitumor protein gene of streptococcus pyogenes su, plasmids containing the gene, transformant cells harboring the plasmids, and process for producing the antitumor protein |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| JPH0253490A (ja) | 1988-08-16 | 1990-02-22 | Agency Of Ind Science & Technol | アルギニン・デイミナーゼ遺伝子 |
| WO1990005534A1 (en) | 1988-11-23 | 1990-05-31 | Genentech, Inc. | Polypeptide derivatives |
| JP2900279B2 (ja) | 1989-08-02 | 1999-06-02 | 株式会社ジャパンエナジー | 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤 |
| JP2736145B2 (ja) | 1990-01-11 | 1998-04-02 | 関東電化工業株式会社 | パーハロゲン化エチレンの製造法 |
| JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| JP3209338B2 (ja) | 1990-09-10 | 2001-09-17 | 株式会社ジャパンエナジー | ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法 |
| US5372942A (en) * | 1992-02-10 | 1994-12-13 | Coriell Institute For Medical Research | Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent |
| WO1994005332A2 (en) | 1992-09-01 | 1994-03-17 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
| US5695760A (en) | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
| US5804183A (en) | 1997-01-31 | 1998-09-08 | Enzon, Inc. | Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US6180387B1 (en) | 1997-08-11 | 2001-01-30 | Smithkline Beecham Corporation | Arginine deiminase |
-
1998
- 1998-02-13 US US09/023,809 patent/US6183738B1/en not_active Expired - Lifetime
- 1998-05-12 DK DK98922197T patent/DK0981607T3/da active
- 1998-05-12 AT AT98922197T patent/ATE335814T1/de active
- 1998-05-12 CN CNB988050668A patent/CN1169951C/zh not_active Expired - Lifetime
- 1998-05-12 JP JP54937598A patent/JP4456184B2/ja not_active Expired - Lifetime
- 1998-05-12 CA CA002288948A patent/CA2288948C/en not_active Expired - Lifetime
- 1998-05-12 ES ES98922197T patent/ES2270515T3/es not_active Expired - Lifetime
- 1998-05-12 WO PCT/US1998/009575 patent/WO1998051784A1/en not_active Ceased
- 1998-05-12 EP EP98922197A patent/EP0981607B1/en not_active Expired - Lifetime
- 1998-05-12 TW TW087107257A patent/TW368504B/zh not_active IP Right Cessation
- 1998-05-12 AU AU74798/98A patent/AU724907B2/en not_active Expired
- 1998-05-12 PT PT98922197T patent/PT981607E/pt unknown
- 1998-05-12 DE DE69835515T patent/DE69835515T2/de not_active Expired - Lifetime
-
2000
- 2000-11-28 US US09/723,546 patent/US6737259B1/en not_active Expired - Lifetime
-
2004
- 2004-01-15 US US10/757,843 patent/US7323167B2/en not_active Expired - Lifetime
-
2006
- 2006-11-03 CY CY20061101590T patent/CY1105758T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU7479898A (en) | 1998-12-08 |
| JP4456184B2 (ja) | 2010-04-28 |
| CN1255944A (zh) | 2000-06-07 |
| US6183738B1 (en) | 2001-02-06 |
| US6737259B1 (en) | 2004-05-18 |
| WO1998051784A1 (en) | 1998-11-19 |
| CA2288948A1 (en) | 1998-11-19 |
| JP2001524836A (ja) | 2001-12-04 |
| EP0981607A1 (en) | 2000-03-01 |
| EP0981607B1 (en) | 2006-08-09 |
| DK0981607T3 (da) | 2006-12-11 |
| PT981607E (pt) | 2006-11-30 |
| US20050129706A1 (en) | 2005-06-16 |
| ES2270515T3 (es) | 2007-04-01 |
| DE69835515T2 (de) | 2007-08-09 |
| US7323167B2 (en) | 2008-01-29 |
| ATE335814T1 (de) | 2006-09-15 |
| TW368504B (en) | 1999-09-01 |
| DE69835515D1 (de) | 2006-09-21 |
| CA2288948C (en) | 2007-10-30 |
| EP0981607A4 (en) | 2004-09-01 |
| CN1169951C (zh) | 2004-10-06 |
| AU724907B2 (en) | 2000-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105758T1 (el) | Τροποποιημενη απιμιναση αργινινης | |
| CY1122841T1 (el) | Πολυαλκυλενικες πολυμερικες ενωσεις και χρησεις αυτων | |
| DE69708100D1 (de) | Konjugate von cis-docosahexaensäure und paclitaxel | |
| DK0914116T3 (da) | Kompositstoffer omfattende konjugater af cis-docosahexaensyre og Taxotere | |
| HN1996000017A (es) | Isotiazolonas | |
| EA199801031A1 (ru) | Ингибиторы протеинфарнезилтрансферазы | |
| CY1120070T1 (el) | Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους | |
| CY1112458T1 (el) | Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου | |
| CY1113347T1 (el) | Πεπτιδια που μειωνουν τα επιπεδα της γλυκοζης στο αιμα | |
| ES2110386T3 (es) | Conjugados de interferon. | |
| CY1108845T1 (el) | Συνδυασμοι οι οποιοι περιεχουν εναν αντιδιαρροϊκο παραγοντα και μια εποθιλονη ή ενα παραγωγο εποθιλονης | |
| DE60010098D1 (de) | 28-epirapaloge | |
| DK0960107T3 (da) | 6-Thiosubstituerede paclitaxeler | |
| CY1107493T1 (el) | Μεθοδοι και συνθεσεις για την προληψη ανεκτικοτητας στα βρογχοδιασταλτικα | |
| CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
| TR200102029T2 (tr) | 1-Heterosiklil ikameli diarilaminler. | |
| CY1110416T1 (el) | Δικυκλικα παραγωγα ιμιδαζ-5-υλ-αμινης | |
| DK0960127T3 (da) | Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf | |
| CY1106870T1 (el) | Σταθεροποιηση ραπαμυκινης ή παραγωγων ραπαμυκινης | |
| CY1108470T1 (el) | Πεπτιδια και πεπτιδομιμητες που εχουν αντι-πολλαπλασιαστικη δραστικοτητα και/ή τα οποια ενισχυουν παραγοντες ή αγωγες που προκαλουν βλαβη στο dna | |
| DK0827537T3 (da) | Chromatin-regulator-gener | |
| CY1106443T1 (el) | 17β-αμινο και υδροξυλαμινο -11β- αρυλστepοειδη και παραγωγα αυτων που εχουν αγωνιστη ή ανταγωνιστη ορμονικες ιδιοτητες | |
| BR9913533A (pt) | Processos para tratar hipertensão e composições para uso nos mesmos | |
| CY1106444T1 (el) | 17b-νιτρο-11β-αρυλοστepοειδη και παραγωγα αυτων ως ορμονικοι αγωνιστες ή ανταγωνιστες | |
| CY1107636T1 (el) | Πρωτεϊνες moraxella catarrhalis |